GS Paper 4 (Ethics)Bioethics and genetic data

You are the Director of the National Bioethics Commission who is responsible for assessing the ethical feasibility and oversight of a nationwide genome sequencing program. The project named GeneFuture, aims to sequence the DNA of every newborn child and store it in a centralized national database. The objective is to identify genetic predispositions to serious diseases early in life, allowing for preventive treatment and personalized medicine. Over 100,000 babies have already been enrolled in the pilot phase of the program. The government claims that this move is a landmark step in public health advancement. However, collection of newborn genetic data raises significant ethical concerns, particularly around informed consent, which may not fully capture parents’ understanding of the long-term risks involved. Once gathered, this sensitive data could be misused for purposes such as surveillance, insurance discrimination, or commercial marketing by third parties. Uncertainty over data ownership, whether it lies with the state, parents, or the individual child’s future, further complicates the issue. The involvement of private tech and pharmaceutical companies heightens fears of commercial exploitation, especially in the absence of clear mechanisms for individuals to withdraw consent or delete their genetic information upon reaching adulthood. (a) What are the ethical issues you perceive in the implementation of the GeneFuture program? (b) Identify the conflicting interests of different stakeholders in this case. (c) What guiding ethical principles would you recommend for implementation of this project?

Based on 17 evaluated answers to this question on CollectorBabu: here is what aspirants most often missed, the mistakes that cost marks, and a model answer.

What most aspirants missed

  • Children cannot consent at birth, and the right to genetic self-determination at adulthood is rarely addressed.
  • A sunset clause that deletes data at 18 unless the individual re-consents, which directly tackles withdrawal.
  • Specific legal safeguards such as GINA in the US, and the DPDP Act, 2023 in India, against genetic discrimination in insurance and employment.
  • International precedents: Iceland's deCODE controversy and the UK Biobank opt-in consent model.
  • Data security protocols, encryption and breach notification as ethical requirements.
  • An independent ethics committee with diverse representation and specific oversight of private company access.

Common mistakes

  • Listing many issues without linking them to bioethics principles such as autonomy, non-maleficence and justice.
  • Naming Puttaswamy or trusteeship without applying them to the case.
  • Vague stakeholder analysis that omits children, future generations and insurers.
  • Proposing a fresh pilot even though 100,000 babies are already enrolted, which shows the answer ignored the case facts.
  • Overlong ethics lists that repeat consent and commercial exploitation points.

What the better answers did

  • Linking each ethical issue to a named principle such as autonomy or non-maleficence.
  • Giving concrete stakeholder clashes, for example parents seeking prevention versus fearing discrimination.
  • Recommending specific safeguards: a sunset clause, GINA-style law, encryption, an independent ethics committee.
  • Ending with a clear recommendation for the existing pilot cohort, such as audit and re-consent.

Introduction

Open by noting that the newborn cannot consent and that the data is lifelong, which frames the whole answer around autonomy and future harm.

Conclusion

Close by recommending an audit and re-consent of the 100,000 enrolled babies, with a sunset clause, so public health gains do not override the child's future autonomy.

Model answer

GeneFuture offers early detection and personalised medicine, but sequencing every newborn raises serious ethical questions. The child cannot consent, the data is permanent, and misuse can harm the child for life. The answer below sets out the issues, stakeholder conflicts and guiding principles.

(a) Ethical issues

  • Informed consent: Parents consent on the child's behalf and may not grasp long-term risks. This weakens the principle of autonomy.
  • Genetic privacy: Privacy is protected under Article 21 (Puttaswamy, 2017). Surveillance or sale of genetic data breaches it.
  • Discrimination: Insurance premium hikes, employment bias and social stigma are real risks. Without legal safeguards, non-maleficence is violated.
  • Future autonomy: The adult may not want to know or be tested. The right to genetic self-determination needs a working mechanism.
  • Ownership and security: It is unclear whether the state, parents or the child owns the data. Hacking and foreign access threaten data sovereignty.

(b) Conflicting interests

  • Parents want disease prevention but fear future discrimination against their child.
  • The government seeks public health gains, while citizens seek privacy and trust.
  • Pharma and tech firms seek commercial returns, which clash with public trust and the child's interests.
  • Insurers want risk-based premiums, which conflicts with the newborn's right to fair cover.
  • Researchers want large datasets, while future adults want control over their own data.

(c) Guiding principles

  • Autonomy: Re-consent at 18, with a sunset clause that deletes data unless the adult opts in.
  • Non-maleficence: Encryption, access controls, breach notification and a GINA-style anti-discrimination law, alongside the DPDP Act, 2023.
  • Justice and beneficence: Equitable access to benefits and benefit-sharing with marginalised communities.
  • Transparency and accountability: An independent ethics committee with diverse representation, IRB-style review of private access, and genetic counselling for families.

GeneFuture should be paused for an audit and re-consent of the 100,000 enrolled babies, anchored in the UNESCO Declaration on Human Genetic Data and lessons from deCODE and UK Biobank. Public health gains are valid only if the child's future autonomy is protected.

Write this answer and get it evaluated

Handwritten answers, expert-reviewed, back in under 24 hours. Start UPSC Mains answer evaluation with the ₹49 Trial.

Evaluate my answer

More GS Paper 4 (Ethics) questions